JP2003535033A5 - - Google Patents

Download PDF

Info

Publication number
JP2003535033A5
JP2003535033A5 JP2001532720A JP2001532720A JP2003535033A5 JP 2003535033 A5 JP2003535033 A5 JP 2003535033A5 JP 2001532720 A JP2001532720 A JP 2001532720A JP 2001532720 A JP2001532720 A JP 2001532720A JP 2003535033 A5 JP2003535033 A5 JP 2003535033A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
agent according
antibody
administered
symptom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001532720A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003535033A (ja
Filing date
Publication date
Priority claimed from US09/429,511 external-priority patent/US6346247B1/en
Application filed filed Critical
Publication of JP2003535033A publication Critical patent/JP2003535033A/ja
Publication of JP2003535033A5 publication Critical patent/JP2003535033A5/ja
Pending legal-status Critical Current

Links

JP2001532720A 1999-10-28 2000-10-27 腸管腔に投与されるポリクローナル抗体による自己免疫疾患の予防および治療 Pending JP2003535033A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/429,511 1999-10-28
US09/429,511 US6346247B1 (en) 1999-10-28 1999-10-28 Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
PCT/US2000/041688 WO2001030300A2 (en) 1999-10-28 2000-10-27 Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies

Publications (2)

Publication Number Publication Date
JP2003535033A JP2003535033A (ja) 2003-11-25
JP2003535033A5 true JP2003535033A5 (enExample) 2007-12-20

Family

ID=23703574

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001532720A Pending JP2003535033A (ja) 1999-10-28 2000-10-27 腸管腔に投与されるポリクローナル抗体による自己免疫疾患の予防および治療

Country Status (8)

Country Link
US (1) US6346247B1 (enExample)
EP (2) EP1949914A1 (enExample)
JP (1) JP2003535033A (enExample)
AT (1) ATE386543T1 (enExample)
AU (1) AU3436901A (enExample)
CA (1) CA2388338A1 (enExample)
DE (1) DE60038122T2 (enExample)
WO (1) WO2001030300A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2490804C (en) * 2002-06-28 2016-12-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating autoimmune diseases with interferon-beta and il-2r antagonist
WO2004034988A2 (en) * 2002-10-16 2004-04-29 Amgen Inc. Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
WO2005014653A2 (en) * 2003-02-28 2005-02-17 Protein Design Labs, Inc. Humanized chicken antibodies
US7883703B2 (en) * 2003-11-14 2011-02-08 The Brigham And Women's Hospital, Inc. Methods of modulating immunity
CN1291231C (zh) * 2003-12-08 2006-12-20 胡军 活化淋巴细胞特异性的检测方法
US20070237717A1 (en) * 2004-04-05 2007-10-11 Roland Martin Methods for Selection of Subjects for Multiple Sclerosis Therapy
CA2667613A1 (en) * 2006-10-26 2008-06-05 Wisconsin Alumni Research Foundation Methods for reducing phosphate absorption
BRPI0918842A2 (pt) * 2008-08-28 2015-12-08 Abbott Biotherapeutics Corp método para tratar pacientes com esclerose múltipla com anticorpos anti-il2r
JP2011026252A (ja) * 2009-07-27 2011-02-10 Kitasato Institute 上皮成長因子受容体に対する卵黄抗体およびその用途
DE102011006809A1 (de) 2011-04-05 2012-10-11 Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0753669B2 (ja) * 1985-11-25 1995-06-07 株式会社ゲン・コーポレーション 鶏卵からの特異的抗体含有材料およびその製造方法と用途
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5945397A (en) 1989-09-05 1999-08-31 Immunex Corporation Purified p75 (type II) tumor necrosis factor receptor polypeptides
CN1061623A (zh) 1990-06-01 1992-06-03 里珍纳龙药品有限公司 睫状神经营养性因子受体
JP3195631B2 (ja) * 1991-02-16 2001-08-06 太陽化学株式会社 特異的鶏卵抗体の製造方法
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US5955290A (en) 1991-12-02 1999-09-21 Regeneron Pharmaceuticals, Inc. Assay systems using the CNTF signal transduction pathway
US5955291A (en) 1992-01-09 1999-09-21 Alitalo; Kari Antibodies recognizing tie receptor tyrosine kinase and uses thereof
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6469017B1 (en) * 1998-01-16 2002-10-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
EP0673389A1 (en) 1992-11-19 1995-09-27 Dana Farber Cancer Institute Antibodies for gm-csf receptor and uses thereof
CA2148907C (en) * 1992-12-29 2008-07-08 Rebecca H. R. Ward Treatment of inflammatory bowel disease with ifn-gamma inhibitors
US5891679A (en) 1993-02-03 1999-04-06 N.V. Innogenetics S.A. TNF-alpha muteins and a process for preparing them
WO1995004075A1 (en) 1993-07-28 1995-02-09 Medvet Science Pty. Ltd. Haemopoietic growth factor antagonists
US5959085A (en) 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US5902584A (en) 1994-02-08 1999-05-11 Ludwig Institute For Cancer Research Antibodies which bind the G-CSF receptor extracelluar domain and methods of treatment
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
IT1269989B (it) 1994-09-21 1997-04-16 Dompe Spa Antagonisti recettoriali di il-1 ad aumentata attivita' inibitoria
US6599719B2 (en) * 1994-11-07 2003-07-29 Human Genome Sciences, Inc. Nucleic acid molecules encoding tumor necrosis factor-gamma-alpha
US5614191A (en) 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
ES2305024T3 (es) 1995-08-01 2008-11-01 F. Hoffmann-La Roche Ag Receptores para interleuquina-12 humana.
US5792850A (en) 1996-05-23 1998-08-11 Zymogenetics, Inc. Hematopoietic cytokine receptor
WO1998013495A1 (en) 1996-09-25 1998-04-02 British Biotech Pharmaceuticals Limited Human rantes mutants incapable of aggregate formation
WO1998014209A1 (en) * 1996-10-02 1998-04-09 Ovimmune, Inc. Oral administration of chicken yolk antibodies to treat disease
US5969105A (en) 1996-10-25 1999-10-19 Feng; Yiqing Stem cell factor receptor agonists
US5945511A (en) 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
US5955303A (en) 1997-03-06 1999-09-21 Incyte Pharmaceuticals, Inc. Human chemokine receptor-like protein
US5945310A (en) 1997-05-19 1999-08-31 Smithkline Beecham Corporation DNA encoding members of the IL-1 family, IL-1 delta
US5891432A (en) 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
US5965704A (en) 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
US6350860B1 (en) * 1997-08-18 2002-02-26 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
US5958442A (en) 1997-10-24 1999-09-28 Bristol-Myers Squibb Company Oncostatin M for treating inflammation
US5968524A (en) 1997-12-23 1999-10-19 Genesis Research & Development Corp. Methods and compounds for the treatment of immunologically-mediated psoriasis

Similar Documents

Publication Publication Date Title
JP2002535285A5 (enExample)
ATE535255T1 (de) Anti-tnf antikörper und methotrexat zur gleichzeitigen behandlung von autoimmunkrankheiten
RU2005126412A (ru) Сор1 для лечения воспалительных заболеваний кишечника
JP2002534479A5 (enExample)
CA2388338A1 (en) Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
HUP0202525A2 (hu) Mofetil mikofenolát és PEG-IFN-alfa együttes alkalmazása, valamint az azokat tartalmazó gyógyszerkészítmények és kit
Hill et al. Juvenile dermatomyositis
Mintz Autologous Transfusion Endorsed-Reply
Ginsburg et al. Treatment of severe esophageal Crohn's disease with thalidomide
JP2001288110A5 (enExample)
Baker 3-drug therapy reduces deaths and new AIDS-related illnesses by 50%
IL94330A0 (en) Pharmaceutical composition comprising gonadotropin releasing hormone
Marshall Buccal lichen planus and carcinoma
Rais et al. Management of Stroke through Virechana
SU1279618A1 (ru) Способ лечени дуоденостаза
RU2002113978A (ru) Способ стимуляции моторной активности кишечника
Bechter et al. Negative symptoms improved by CSF filtration in a case of recent onset schizophrenia
Krementz et al. The treatment of soft-tissue sarcoma by chemotherapy
Coutinho et al. Zuclopenthixol acetate in psychiatric emergencies: Looking for evidence from clinical trials
D'Amico How HIV does its dirty work
Gelfand Medical Aspects Of Witchcraft Practice Among The Shona People Of Rhodesia
Meize-Grochowski When the DX is Crohn's disease.
Sigalet A comparison of surgical versus medical treatment of the short bowel syndrome
James 3TC: combination trial stopped early as clinical benefit shown
Centers for Disease Control and Prevention Publication of Surgeon General's report on smoking and health